peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
Hansa Biopharma
HNSA (, %) SEK
Hansa Biopharma
Coffee and notepad

Press releases

2022

30 Sep 2022, 08:00

· Award granted by internationally recognized Great Place to Work[®] institute.
· Certification based on company-wide survey completed by 99% of Hansa employees.
· Metrics related to trust in the company, credibility, pride and fairness, continue to be among those most highly rated by employees.
22 Aug 2022, 14:00

· Idefirix[®] (imlifidase) becomes the first and only product reimbursed for the desensitization of highly sensitized patients waiting for a kidney transplant in Poland
· Reimbursement follows the inclusion of Idefirix[®] on the shortlist for exceptional innovative treatments with special funding   
· The reimbursement decision provides highly sensitized patient…
10 Aug 2022, 08:00

· European guidelines target the management of highly sensitized kidney transplant patients (patients with human leukocyte antigen (HLA) antibodies)
· These guidelines provide a new clinical practice tool for healthcare professionals to help achieve the best possible outcomes for highly sensitized kidney patients 
· Hansa Biopharma sponsors desensitization works…
19 Jul 2022, 08:00 | Regulatory
•    Continued solid sales in Q2
•    Positive NICE recommendation obtained 
•    Completed enrollment in imlifidase Phase 2 program in AMR 
•    Peter Nicklin elected as new Chairman of the Board of Directors
Load more

Coffee and notepad

E-mail

Sign up to receive updates on the latest company news and filings

Choose type

Thank you. You will get an e-mail message to activate your subscription.